Avant Technologies Inc. (AVAI) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $14.0M is the value of all shares combined. Beta 1.06: the stock has moved about 6% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAvant Technologies Inc. (AVAI) trades at $0.101. Avaí Bio, Inc. is a technology company focused on acquiring and developing artificial intelligence (AI) technologies, along with providing IT consulting services. Market cap: $14.0M, Sector: Technology.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for AVAI: AVAI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AVAI against Technology peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
AVAI: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Avant Technologies Inc. (AVAI) Technology Profile & Competitive Position
Avaí Bio, Inc., based in Vilnius, Lithuania, specializes in AI technology development and IT consulting. The company offers full-stack software solutions, database management, and its Avant! AI platform. With a market capitalization of $14.0M, Avaí Bio operates in the competitive application software sector, focusing on AI-driven innovations.
What Is the Investment Thesis for AVAI?
Avaí Bio, Inc. presents a speculative investment opportunity within the AI and IT consulting sectors. The company's focus on AI technology development, particularly the Avant! AI platform, could drive future growth, though specific performance metrics are not available. With a market capitalization of $14.0M and negative free cash flow, the company's financial position requires careful monitoring. Key catalysts include successful commercialization of Avant! AI and strategic acquisitions to expand its technology portfolio. Potential risks include competition in the AI space and the challenges of integrating acquired technologies. Investors should carefully assess the company's ability to execute its growth strategy and achieve profitability.
Based on FMP financials and quantitative analysis
AVAI Key Highlights
Market capitalization of $14.0M, indicating a small-cap company.
- Negative Free Cash Flow (FCF) of $0.00 billion, suggesting the company is not currently generating positive cash flow from operations.
- Beta of 1.06, implying the stock's volatility is similar to the overall market.
- The company rebranded from Avant Technologies Inc. to Avaí Bio, Inc. in February 2026, reflecting a strategic shift towards biotechnology and AI.
- Avaí Bio, Inc. offers Avant! AI, a platform that aims to deliver enhanced technology usage, access, and performance.
Who Are AVAI's Competitors?
AVAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MNDO MIND C.T.I. Ltd. | $1.02 | +3.00% | $20.9M | 795-pillar |
| IDN Intellicheck, Inc. | $2.62 | +0.77% | $53.1M | 765-pillar |
| WFCF Where Food Comes From, Inc. | $13.20 | +3.94% | $66.5M | 725-pillar |
| TRAK ReposiTrak, Inc. | $7.89 | +0.25% | $143M | 785-pillar |
| PERF Perfect Corp. | $1.93 | +0.52% | $197M | 865-pillar |
| IMMR Immersion Corporation | $7.36 | -1.08% | $244M | 785-pillar |
| RMNI Rimini Street, Inc. | $4.58 | +0.11% | $427M | 775-pillar |
| MTLS Materialise NV | $7.64 | +2.83% | $447M | 755-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVAI's Key Strengths?
Focus on artificial intelligence (AI) technologies.
- Offers a range of IT consulting services.
- Provides full-stack software development capabilities.
- Avant! AI platform with potential for enhanced technology usage.
What Are AVAI's Weaknesses?
Negative Free Cash Flow (FCF) indicating financial challenges.
- Limited information available on the performance of Avant! AI.
- Small market capitalization, making it vulnerable to market fluctuations.
- Reliance on acquisitions for growth, which can be risky.
What Could Drive AVAI Stock Higher?
Potential partnerships with established technology vendors to integrate Avant! AI into existing software ecosystems.
- Development and release of new AI-powered applications for specific industries.
- Strategic acquisitions of complementary AI technologies and IT consulting firms to expand market reach.
- Expansion of IT consulting services to new geographic markets with high demand.
- Continued refinement and enhancement of the Avant! AI platform.
What Are the Key Risks for AVAI?
Financial-distress signal — its Altman Z-Score of -21.05 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the AI and IT consulting markets could limit market share.
- Rapid technological advancements may render existing solutions obsolete.
- Economic downturns could reduce demand for IT services and AI solutions.
- Negative Free Cash Flow (FCF) indicating financial challenges and potential need for additional funding.
- Lower liquidity and greater price volatility associated with trading on the OTCQB market.
What Are the Growth Opportunities for AVAI?
- Growth opportunity 1: Successful commercialization of Avant! AI represents a significant growth opportunity for Avaí Bio. The platform's ability to deliver enhanced technology usage, access, and performance could attract businesses seeking to leverage AI for various applications. While specific market size data for AI platforms is not available, the broader AI market is projected to experience substantial growth in the coming years. The timeline for commercialization will depend on the company's ability to refine the platform and secure partnerships with key customers.
- Growth opportunity 2: Strategic acquisitions of complementary AI technologies and IT consulting firms could accelerate Avaí Bio's growth. By acquiring companies with established customer bases and specialized expertise, Avaí Bio can expand its market reach and enhance its service offerings. The market for technology acquisitions remains active, with numerous opportunities to acquire innovative companies. The timeline for acquisitions will depend on the company's ability to identify suitable targets and secure financing.
- Growth opportunity 3: Expansion of IT consulting services to new geographic markets represents another growth opportunity for Avaí Bio. By targeting regions with high demand for IT services and limited competition, the company can increase its revenue and market share. The global IT services market is projected to continue growing in the coming years, driven by digital transformation initiatives and the increasing complexity of IT infrastructure. The timeline for geographic expansion will depend on the company's ability to establish a local presence and adapt its services to meet the specific needs of each market.
- Growth opportunity 4: Development of new AI-powered applications for specific industries could create new revenue streams for Avaí Bio. By focusing on niche markets with unmet needs, the company can differentiate itself from competitors and capture a significant share of the market. The market for AI-powered applications is rapidly evolving, with new opportunities emerging across various industries. The timeline for developing new applications will depend on the company's ability to identify promising market segments and develop innovative solutions.
- Growth opportunity 5: Leveraging partnerships with established technology vendors to integrate Avant! AI into existing software ecosystems could drive adoption and generate revenue. By collaborating with companies that have a large customer base and a strong market presence, Avaí Bio can reach a wider audience and accelerate the commercialization of its AI platform. The market for technology partnerships is highly competitive, but successful collaborations can create significant value for both parties. The timeline for establishing partnerships will depend on the company's ability to demonstrate the value of its AI platform and negotiate favorable terms.
What Are AVAI's Competitive Advantages?
- Proprietary AI technology through its Avant! AI platform.
- Expertise in full-stack software development and IT consulting.
- Strategic acquisitions of complementary technologies and companies.
- Established presence in the IT consulting market.
What Does AVAI Do?
Avaí Bio, Inc., incorporated in 2017 and based in Vilnius, Lithuania, is a technology company focused on acquiring, creating, and developing artificial intelligence (AI) technologies. Originally founded as Avant Technologies Inc., the company rebranded to Avaí Bio, Inc. in February 2026, signaling a strategic shift towards biotechnology and AI. The company offers a range of information technology (IT) consulting services, including full-stack software development, database management, data integration, project management, and cloud services resources. Avaí Bio's product portfolio includes Avant! AI, an AI platform designed to deliver enhanced technology usage, access, and performance. Additionally, the company offers InstantFAME, though specific details of this product are not provided. Avaí Bio aims to provide comprehensive technology solutions and consulting services to businesses seeking to leverage AI and advanced IT capabilities. The company operates primarily in the technology sector, focusing on software applications and AI-driven solutions. Avaí Bio seeks to establish itself as a key player in the AI technology space through strategic acquisitions and internal development efforts.
What Products and Services Does AVAI Offer?
- Acquires and develops artificial intelligence (AI) technologies.
- Offers information technology (IT) consulting services.
- Provides full-stack software development.
- Offers database management services.
- Provides data integration solutions.
- Offers project management resources.
- Provides cloud services resources.
- Offers Avant! AI, an AI platform.
How Does AVAI Make Money?
- Provides IT consulting services on a project basis or through managed services agreements.
- Generates revenue from the sale or licensing of its AI platform, Avant! AI.
- Acquires and develops AI technologies, potentially monetizing them through licensing or sale.
- Offers software development services to clients.
What Industry Does AVAI Operate In?
Avaí Bio, Inc. operates within the application software industry, a segment of the broader technology sector characterized by rapid innovation and intense competition. Avaí Bio's focus on AI technology aligns with these trends, but the company faces competition from established players and emerging startups. The company's success will depend on its ability to differentiate its AI offerings and effectively market its IT consulting services.
Who Are AVAI's Key Customers?
- Businesses seeking to leverage AI for various applications.
- Organizations requiring IT consulting services.
- Companies needing software development and database management solutions.
- Clients looking for data integration and project management support.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 42 |
| 2026-08-26 | 42 |
| 2026-08-29 | 42 |
| 2026-09-01 | 42 |
| 2026-09-04 | 42 |
| 2026-09-07 | 42 |
| 2026-09-10 | 42 |
What changed?
The score has stayed at 42.
Over the same 18 days the stock moved -15.2%.
Key Financial Metrics
Return on equity for Avant Technologies Inc. stands at 47.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -4.7%, the inverse of the P/E and a quick read on earnings relative to price.
Avant Technologies Inc. (AVAI) Valuation Context
Valued at $14.0M, AVAI is classified as a micro-cap stock.
Company Profile
Avant Technologies Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Vilnius, LT. The company is led by CEO Chris Winter. AVAI has traded publicly since 2020.
Financial Health
Avant Technologies Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.05 places it in the distress zone, a signal of elevated financial risk.
AVAI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on artificial intelligence (AI) technologies.
- Offers a range of IT consulting services.
- Provides full-stack software development capabilities.
- Avant! AI platform with potential for enhanced technology usage.
Bear Case
- Negative Free Cash Flow (FCF) indicating financial challenges.
- Limited information available on the performance of Avant! AI.
- Small market capitalization, making it vulnerable to market fluctuations.
- Reliance on acquisitions for growth, which can be risky.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AVAI Latest News
-
Avant Brands Completes EU GMP Audit at Flowr Facility
accessnewswire.com · Aug 20, 2026
-
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
globenewswire.com · Aug 12, 2026
-
Avant Brands Completes Major LED Lighting Retrofit at its 80,000 Sq Ft Flowr Facility, Delivering Significant Energy Savings & Production Gains
accessnewswire.com · Jul 22, 2026
-
Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy
prnewswire.com · Jul 21, 2026
AVAI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AVAI.
Price Targets
Wall Street price target analysis for AVAI.
AVAI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AVAI; grades run from A+ (80-100) to F (below 30).
Latest News
Avant Brands Completes EU GMP Audit at Flowr Facility
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
Avant Brands Completes Major LED Lighting Retrofit at its 80,000 Sq Ft Flowr Facility, Delivering Significant Energy Savings & Production Gains
Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy
AVAI OTC Market Information
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market for U.S. companies. OTCQB companies must meet certain financial reporting standards, undergo annual verification and management certification, and meet a minimum bid price test. This tier offers more transparency than the Pink market but less than the major exchanges like NYSE or NASDAQ. Companies on OTCQB are generally early-stage or developing companies.
- OTC Tier: OTC Other
- Lower liquidity compared to major exchanges, potentially leading to difficulty in buying or selling shares.
- Less stringent listing requirements than NYSE or NASDAQ, increasing the risk of financial instability.
- Greater price volatility due to lower trading volume and market capitalization.
- Potential for limited analyst coverage and investor awareness.
- Risk of delisting if the company fails to meet OTCQB requirements.
- Verify the company's financial reporting and disclosures on the OTC Markets Group website.
- Review the company's business plan and growth strategy.
- Assess the company's management team and their track record.
- Analyze the company's competitive position within the AI and IT consulting markets.
- Evaluate the company's capital structure and ability to raise additional funding.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor to assess the risks and potential rewards of investing in AVAI.
- Current disclosure status on the OTCQB market.
- Company's focus on artificial intelligence (AI) technologies, a high-growth sector.
- Provision of IT consulting services, indicating a revenue-generating business.
- Rebranding to Avaí Bio, Inc. to reflect a strategic focus on biotechnology and AI.
- Incorporation in 2017, suggesting a relatively established operating history.
Avant Technologies Inc. Technology Stock: Key Questions Answered
Is AVAI a good stock?
Stock Expert AI does not rate AVAI buy, sell or hold. Avant Technologies Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about AVAI stock?
As of March 15, 2026, analyst coverage of Avaí Bio, Inc. (AVAI) is limited due to its small market capitalization and listing on the OTCQB market. Key valuation metrics, such as price-to-earnings ratio, are not readily available due to the company's negative free cash flow.
What are the main risks for AVAI?
The main risks for Avaí Bio, Inc. include intense competition in the AI and IT consulting markets, which could limit its market share and profitability. Economic downturns could reduce demand for IT services and AI solutions, impacting revenue.
What are the key factors to evaluate for AVAI?
Evaluate AVAI on fundamentals, analyst consensus, and risk factors. Avaí Bio, Inc. presents a speculative investment opportunity within the AI and IT consulting sectors. Not financial advice.
How frequently does AVAI data refresh on this page?
AVAI's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AVAI's recent stock price performance?
Avant Technologies Inc. (AVAI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on artificial intelligence (AI) technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AVAI overvalued or undervalued right now?
Avant Technologies Inc. (AVAI) is loss-making, so its trailing P/E is negative (-102.09x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AVAI?
Yes, most major brokerages offer fractional shares of Avant Technologies Inc. (AVAI) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for in-depth analysis.
- OTC market carries higher risks than major exchanges.